Larimar Therapeutics, Inc.
LRMR · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Operating Activities | – | – | – | – |
| Net Income | -$80,604 | -$36,949 | -$35,355 | -$50,636 |
| Dep. & Amort. | $318 | $311 | $318 | $326 |
| Deferred Tax | $0 | $0 | $0 | $0 |
| Stock-Based Comp. | $8,796 | $0 | $6,619 | $5,473 |
| Change in WC | $6,175 | -$2,511 | $1,669 | $2,747 |
| Other Non-Cash | -$5,445 | $5,690 | -$820 | -$15 |
| Operating Cash Flow | -$70,760 | -$33,459 | -$27,569 | -$42,105 |
| Investing Activities | – | – | – | – |
| PP&E Inv. | -$515 | -$164 | -$100 | -$333 |
| Net Acquisitions | $0 | $0 | $91 | -$25 |
| Inv. Purchases | -$227,872 | -$101,233 | -$133,610 | -$8,248 |
| Inv. Sales/Matur. | $143,000 | $134,750 | $42,750 | $32,750 |
| Other Inv. Act. | $0 | $0 | -$91 | $25 |
| Investing Cash Flow | -$85,387 | $33,353 | -$90,960 | $24,169 |
| Financing Activities | – | – | – | – |
| Debt Repay. | $0 | $0 | $0 | $0 |
| Stock Issued | $161,806 | $30 | $75,257 | $19,885 |
| Stock Repurch. | $0 | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 |
| Other Fin. Act. | $77 | $0 | $0 | $0 |
| Financing Cash Flow | $161,883 | $30 | $75,257 | $19,885 |
| Forex Effect | $0 | $0 | $0 | $0 |
| Net Chg. in Cash | $5,736 | -$76 | -$43,272 | $1,949 |
| Supplemental Information | – | – | – | – |
| Beg. Cash | $28,088 | $26,825 | $71,436 | $69,487 |
| End Cash | $33,824 | $26,749 | $28,164 | $71,436 |
| Free Cash Flow | -$71,275 | -$33,623 | -$27,669 | -$42,438 |